Navigation Links
Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
Date:8/19/2007

BERKELEY, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the U.S. Patent Office has issued the company a broad composition of matter patent covering the company's proprietary second-generation TLR9 agonists.

The claims cover a broad class of novel TLR9 agonists containing short DNA sequences separated by spacer molecules. These linear chimeric immunomodulatory compounds (CICs), are being developed at Dynavax for application across a wide range of therapeutic categories. The claims cover CICs with or without antigen, and alone or in a pharmaceutical preparation. The current term for this patent expires in June 2022. The patent, U.S. patent No. 7,255,868 B2, was issued August 14, 2007 with inventors Karen Fearon, Dino Dina, M.D., and Stephen Tuck.

According to Dino Dina, M.D., President and Chief Executive Officer, "We developed the second-generation TLR9 agonists specifically to gain broad patent coverage for a full range of products in our pipeline. The issuance of this landmark patent provides broad patent coverage for novel and non-obvious molecules that are completely different from our first generation TLR9 agonists. We have pending applications in this family that we believe have the potential to expand the scope of coverage."

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV, a hepatitis B vaccine in Phase 3; TOLAMBA, a ragweed allergy immunotherapy; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. Our preclinical work on a vaccine for influenza is partially funded by the NIH. Our colorectal cancer trial and our preclinical hepatitis C therapeutic program are funded by Symphony Dynamo, Inc. While the NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.

This press release contains forward-looking statements that are subject to a number of risks and uncertainties, including statements about the scope of our CIC patent coverage and the potential to obtain expanded coverage. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including; the possibility of litigation or other challenges to the validity or scop of our patents, possible claims against us based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our Quarterly Report on Form 10-Q. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.


'/>"/>
SOURCE Dynavax Technologies Corporation

Copyright©2007 PR Newswire.

Related biology technology :

1. Landmark patent law under attack, Bayh says
2. Changes to U.S. patent law must nurture our culture of innovation
3. WARF questions relevancy of documents used to uphold patent challenge
4. Supreme Court limits foreign reach of U.S. patents
5. High court sends message on patent obviousness
6. Supreme Court ruling seen as blow to WARF stem cell patents
7. Patent licensing: For enforcing companies, the rules have changed
8. Patent ruling doesnt tarnish Wisconsins stem cell leadership
9. Heres why Wisconsins stem cell patents are being challenged
10. WARF is likely to hold on to stem cell patent rights
11. Patent office upholds challenge to WARF stem cell patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, a privately ... quarterly travel award to noteworthy scientists who will be presenting research using ACEA ... round of awards are being given to two postdoctoral fellows studying pathogen capture ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - The University of ... Nordion, a business of Sterigenics International, and General Atomics ... been submitted to the U.S. Nuclear Regulatory Commission (NRC). ... production of molybdenum-99 (Mo-99). Once operational, production from this ... U.S. demand for Mo-99, which currently must be imported ...
(Date:3/28/2017)... Hong Kong (PRWEB) , ... March 28, 2017 ... ... has selected NetDimensions Learning to replace paper-based processes and enhance training plan management ... “We are very pleased to partner with the SHL Group to help improve ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of the Modular Building Institute (MBI), an international modular trade organization, were awarded ... modular category for the Pagliuca Life Lab at Harvard University. The awards were ...
Breaking Biology Technology:
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):